
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
health
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
ChipMOS TECHNOLOGIES INC.